Forkhead box C1 induces epithelial-mesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma

LEI OU-YANG1*, SHENG-JUN XIAO2*, PENG LIU1, SHI-JANG YI1, XIAO-LING ZHANG3, SHI OU-YANG4, SHENG-KUI TAN5 and XUN LEI1

1Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001; 2Department of Pathology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541199; 3Department of Physiology, Faculty of Basic Medical Science, Guilin Medical University, Guilin, Guangxi 541004; 4The Liver Disease Center of The PLA, The 458th Hospital of The PLA, Guangzhou, Guangdong 510602; 5Department of Public Health College, Guilin Medical University, Guilin, Guangxi 541004, P.R. China

Received December 2, 2014; Accepted August 24, 2015

DOl: 10.3892/mmr.2015.4427

Abstract. Nasopharyngeal carcinoma (NPC) is a highly invasive malignancy with cervical lymphopathy as the initial presentation. Epithelial-mesenchymal transition (EMT), a process by which epithelial cells lose cell-cell adhesion and gain migratory and invasive properties, has a pivotal role in metastasis. Forkhead box C1 (FoxC1), a member of the forkhead family of transcription factors, induces EMT and has a critical role in metastasis of multiple human cancers. However, the role of FoxC1 in the progression of NPC has remained elusive. The present study revealed that the expression of FoxC1 was markedly elevated in NPC tissues compared with that in chronically inflamed nasopharyngeal tissues and was closely correlated with vimentin, fibronectin and N-cadherin expression as indicated by immunohistochemical assays. In addition, high FoxC1 expression was positively associated with lymph node metastasis, distant metastasis and an advanced clinical stage in patients with NPC. Furthermore, FoxC1 expression was high in NPC cell lines while being low in an immortalized normal nasopharyngeal epithelial cell line. In vitro, knockdown of FoxC1 in the CNE2 human NPC cell line by small interfering RNA downregulated vimentin, fibronectin and N-cadherin expression and reduced the migratory and invasive capacity of CNE2 cells. In conclusion, the present study indicated that FoxC1 has a pivotal role in EMT through the upregulation of vimentin, fibronectin and N-cadherin expression. Thus, FoxC1 may be a potential therapeutic target in NPC.

Introduction

Nasopharyngeal carcinoma (NPC) is an endemic disease and a significant health problem in southern China and south-eastern Asia (1,2). The etiology of NPC includes virological, genetic and environmental factors (3). NPC is radiation-sensitive and chemo-sensitive (4); however for patients who develop local recurrence, there is no efficient systemic remedy. Distant metastasis is the leading cause of mortality of advanced NPC patients (4,5). Epithelial-mesenchymal transition (EMT), a process by which epithelial cells lose epithelial markers and gain mesenchymal markers, endows cancer cells with migratory and invasive properties to initialize metastasis (6-8). In NPC, amongst other cancer types, the EMT was reported to be a key event involved in invasion and metastasis (9).

Forkhead box C1 (FoxC1), a member of the forkhead transcription factor family, was reported to be a regulator of the EMT (10). It is well known that FoxC1 has an important role in embryonic and ocular development (11,12). Recently, accumulating evidence showed that FoxC1 was overexpressed and correlated with metastasis and poor prognosis in several cancer types, including breast cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, Hodgkin lymphoma and lung cancer (13-17). Indeed, FoxC1 induced EMT cells by downregulating E-cadherin to promote cell migration and aggressiveness in breast cancer and hepatocellular carcinoma (10,18-20).

To date, no studies have investigated the clinicopathological significance of FoxC1 and its role in the EMT in NPC. The present study examined NPC tissues and NPC cell lines as well as chronically inflamed nasopharyngeal tissue specimens and an immortalized normal nasopharyngeal epithelial cell line for the expression of FoxC1. In addition, a correlation study was performed to assess the association of FoxC1 with clinicopathological characteristics and the expression of mesenchymal markers in NPC. Furthermore, the role of FoxC1's role in the EMT of NPC was investigated in vitro.
Materials and methods

Tissue specimens. All NPC and chronically inflamed nasopharyngeal tissue specimens were collected from the Affiliated Hospital of Guilin Medical University (Guilin, China) between May 2011, and February 2013. The study protocol was approved by the research ethics committee of the Affiliated Hospital of Guilin Medical University (Guilin, China) and written informed consent was obtained from each patient. All samples were pathologically re-assessed by two pathologists, and the percentage of tumor cells was ≥70% in all NPC specimens. None of the patients had received radiotherapy or chemotherapy prior to biopsy sampling (21). 93 NPC tissue specimens with complete clinical data and 33 NP specimens were collected for constructing tissue microarrays and subjected to further study. The clinicopathological characteristics of the patients are listed in Table I. Clinical staging was performed according to the tumor-nodes-metastasis (TNM) classification system of the International Union Against Cancer staging system (22).

Tissue microarray and immunohistochemical (IHC) analysis. NPC and chronically inflamed nasopharyngeal tissue specimens were subjected to a tissue microarray study performed by Pantomics Inc. (Richmond, VA, USA). Briefly, antigens in tissue slices were retrieved by boiling in citrate buffer (0.01 M; pH 6.0) and samples were stained with FoxC1 antibody (1:100; cat. no. ab5079; goat polyclonal; Abcam, Cambridge, MA, USA) for 1 h at room temperature. Incubation with horseradish peroxidase (HRP)‑conjugated secondary antibody and visualization with diaminobenzidine (DAB) was performed using a MaxVision™-HRP-Polymer IHC kit and a DAB kit from Maxim (Fuzhou, China) according to the manufacturer’s instructions (23). Staining with vimentin antibody (1:50; cat. no. sc-6260; mouse monoclonal; Santa Cruz Biotechnology, Inc, Dallas TX, USA), Fibronectin antibody (1:50; cat. no. sc-18825; mouse monoclonal; Santa Cruz Biotechnology, Inc., N-cadherin antibody (1:100; cat. no. sc-59987; mouse monoclonal; Santa Cruz Biotechnology, Inc.), E-cadherin antibody (1:50; cat. no. sc-7870; rabbit polyclonal; Santa Cruz Biotechnology, Inc.) and β-catenin antibody (1:100; cat. no. 8478; rabbit polyclonal; Cell Signaling Technology, Danvers, MA, USA) was performed in an identical manner.

Scoring of the IHC staining was performed by two pathologists at Guilin Medical College (Guilin, China). Briefly, each sample was assessed by adding up the scores for the intensity and extent of staining. The intensity of staining was scored as follows: 0, negative; 1, weak; 2, intermediate or 3, strong. The extent of staining was scored based on the percentage of positive tumor cells: 0, <5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, >76%. For vimentin, fibronectin and N-cadherin, each case was finally classified as negative and positive, while for FoxC1, E-cadherin and β-catenin, tissues were classified as low (final score, 0-3) and high (final score, 4-7) (10).

Cell line and cell culture. The human NPC cell lines 5-8F, 6-10B, CNE1 and CNE2 as well as the NP69 human immortalized nasopharyngeal epithelial cell line were obtained from the American Type Culture Collection (Manassas, VA, USA). The 5-8F cell line has a high metastatic potential, while that of the 6-10B cell line is low. The CNE1 cell line is well-differentiated, while differentiation of CNE2 cells is low. The NPC cell lines were cultured in RPMI-1640 (Gibco-BRL, Invitrogen Life Technologies, Inc., Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco-BRL) and 0.01% penicillin and streptomycin (Gibco-BRL). NP69 cells were cultured in keratinocyte serum-free medium (Gibco-BRL) without any supplementation. All cells were cultured at 37°C in a humidified incubator in an atmosphere containing 5% CO₂.

FoxC1 knockdown in CNE2 cells by RNA interference. The human FoxC1 small interfering (si)RNA (cat. no. sc-43766) and control siRNA-A (cat. no. sc-37007) were purchased from Santa Cruz Biotechnology, Inc. At 24 h prior to transfection, CNE2 cells were plated at a density of 5x10⁴ cells/well in a six-well plate. When the cells reached 50% confluency, they were transfected with 200 pmol (80 μM) siRNA using Lipofectamine 2000 (Invitrogen Life Technologies, Inc) according to the manufacturer’s instructions. The groups transfected with FoxC1 siRNA and control siRNA were named as siFoxC1 and siNC, respectively. After 6 h of incubation, the cells were washed three times with phosphate-buffered saline (PBS) and the medium was replaced with RPMI-1640 supplemented with 10% FBS. After incubation for 48 h, cells were subjected to western blot analysis and cell motility assays.

Western blot analysis. Western blot analyses were performed using standard methods. Western blot analyses were performed using standard methods. In brief, cell pellets were lysed in radioimmunoprecipitation assay (RIPA) buffer (Beyotime Institute of Biotechnology, Haimen, China) with 1 mM phenylmethanesulfonyl fluoride (Solarbio, Beijing, China). The cell lysate was centrifuged at 10,000 x g for 10 min at 4°C and the supernatant was transferred to a fresh microcentrifuge tube. Protein concentration was determined by the Bicinchoninic Acid Protein Assay Reagent kit (cat. no. 23225; Pierce Biotechnology, Inc., Rockford, IL, USA) and 20 μg protein was loaded per lane. The proteins were separated by 10% SDS-PAGE and electrotransferred onto a 0.45-μm polyvinylidene difluoride membrane (Merck-Millipore, Billerica, MA, USA). The membrane was blocked with 5% nonfat milk in 20 mM Tris-HCl, 150 mM NaCl and 0.1% Tween-20 (pH 7.5) (TBST; Sigma-Aldrich) for 1.5 h and incubated with the respective primary antibodies overnight at 4°C. The dilution of FoxC1 antibody (cat. no. 8758; rabbit polyclonal; Cell Signaling Technology), vimentin antibody (cat. no. sc-6260; mouse monoclonal; Santa Cruz Biotechnology, Inc.), fibronectin antibody (cat. no. sc-18825; mouse monoclonal; Santa Cruz Biotechnology, Inc.), N-cadherin antibody (cat. no. sc-59987; mouse monoclonal; Santa Cruz Biotechnology, Inc.), E-cadherin antibody (cat. no. sc-7870; rabbit polyclonal; Santa Cruz Biotechnology, Inc.) and β-catenin antibody (cat. no. 8478; rabbit polyclonal; Cell Signaling Technology) and β-actin antibody (cat. no. sc-47778; mouse monoclonal; Santa Cruz Biotechnology, Inc.) was 1:1,000. Subsequently, the membranes were washed three times with TBST and incubated with HRP-conjugated secondary antibodies goat anti-rabbit IgG (1:5,000; cat. no. ZDR-5306;
ZsBio, Beijing, China) and goat anti-mouse IgG (1:5,000; cat. no. ZDR-5307; ZsBio) at room temperature for 1.5 h. The bands were visualized using an ECL Plus Western Blot kit (cat. no. sc-2048; Western Blotting Luminol Reagent; Santa Cruz Biotechnology, Inc.). The ChemiDoc™ XRS+ system (Bio-Rad Laboratories, Inc, Hercules, CA, USA) and X-Omat BT film (Carestream Health, Inc, Rochester, NY, USA) were used to capture images of the blots. The intensity of the bands was quantified by densitometry and normalized to that of β-actin (23). The gray values of all bands were measured using Image-pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA).

In vitro migration and invasion assays. An 8-µm pore size Transwell insert (BD Biosciences, Franklin Lakes, NJ, USA) was used to assess the migratory and invasive ability of cells. At 48 h after transfection, 5x10^4 CNE2 cells in serum-free RPMI-1640 were seeded into the upper chamber, which was lined with a non-coated membrane, for Transwell migration assays. For invasion assays, Transwell chambers were washed with serum-free medium and 200 mg/ml Matrigel (BD Biosciences) was added to the polycarbonate membrane and dried overnight under sterile conditions. Subsequently, 1x10^5 cells were seeded in the upper chamber. These inserts were inserted in a 24-well plate with 500 µl RPMI-1640 containing 10% FBS. After incubation for 24 h, the cells on the upper side of the basement membrane were removed with a sterile cotton swab, and the cells that invaded to the lower side of the basement membrane were stained with Giemsa (Sigma-Aldrich). The cells which transgressed through the Transwell polycarbonate membrane were counted under a microscope (BX51; Olympus, Tokyo, Japan). Six random high-power fields were selected for each sample, and the experiment was repeated three times. Results were expressed as mean values of triplicate assays for each experimental condition.

In vitro wound-healing assay. The wound healing assay was performed following a procedure of a previous study (24). CNE2 cells were transfected with siRNA as described above. After incubation for 48 h, the cells were trypsinized (Gibco-BRL) and plated at 5x10^5 cells/ml into six-well plates. After incubation overnight, line-shaped wounds in the cell monolayer were generated using a pipette tip and images were captured at 0, 24 and 48 h using an Olympus BX51 microscope (24). Experiments were performed in triplicate and repeated three times.

Statistical analysis. Values are expressed as the mean ± standard deviation. Categorical data were analyzed using the χ² test or Fisher's exact test. Quantitative data were analyzed by using the Unpaired Student's t-test for comparing two groups and one-way analysis of variance for multiple variant
analysis. \( P<0.05 \) was considered to indicate a statistically significant difference between values and all analyses were performed with using SPSS 19.0 (International Business Machines, Armonk, NY, USA).

**Results**

*FoxC1 is upregulated in NPC tissues and cell lines and high expression of FoxC1 is associated with advanced clinico-pathological characteristics.* To explore the role of FoxC1 in determining clinical outcomes for NPC patients, the present study investigated the expression of FoxC1 in a tissue microarray comprising 93 NPC and 33 chronically inflamed nasopharyngeal tissue specimens. IHC analysis showed that FoxC1 was localized in the nucleus and cytoplasm. High expression of FoxC1 was observed in 40 out of 93 (43.0%) NPC tissues, but in only 4 out of 33 (12.1%) chronically inflamed nasopharyngeal tissues (\( P<0.01 \)) (Fig. 1A). Western blot analysis showed that FoxC1 expression was high in NPC cell lines and low in the NP69 immortalized normal human nasopharyngeal epithelial cell line (Fig. 1B). High expression of FoxC1 was significantly correlated with tumor size, lymph node metastasis, distant metastasis and clinical stage (Table I).

*High expression of FoxC1 is positively correlated with vimentin, fibronectin and N-cadherin expression in NPC tissues.* Compared to cases with low FoxC1, mesenchymal markers vimentin, fibronectin and N-cadherin were upregulated in NPC tissues with high expression of FoxC1. However, the expression levels of E-cadherin and \( \beta \)-catenin showed no significant difference between the high FoxC1 group and the low FoxC1 group (Fig. 2A). Among the 40 cases with high FoxC1 expression, the positive expression rate of vimentin, fibronectin and N-cadherin was 29/40 (72.5%), 25/40 (62.5%) and 39/40 (97.5%), respectively, and the high expression rate of E-cadherin and \( \beta \)-catenin was 26/40 (65.0%) and 24/40 (60.0%), respectively. In the specimens with low FoxC1 expression, the positive expression rate of vimentin, fibronectin and N-cadherin was 22/53 (41.5%), 20/53 (37.7%) and 42/53 (79.3%), respectively, and the high expression rate of E-cadherin and \( \beta \)-catenin was 34/53 (64.2%) and 39/53 (73.6%), respectively (Fig. 2B).

*FoxC1 knockdown by siRNA decreases vimentin, fibronectin and N-cadherin expression in CNE2 cells.* After FoxC1 knockdown by siRNA, the mesenchymal markers vimentin, fibronectin and N-cadherin were downregulated in CNE2 cells. However, the expression of E-cadherin and \( \beta \)-catenin was not significantly different between the knockdown group and the control group (Fig. 3).

*FoxC1 knockdown by siRNA reduces CNE2 cell migration and invasion in vitro.* Transwell assays showed that the number of migrated and invaded CNE2 cells was significantly decreased after FoxC1 knockdown by siRNA (Fig. 4A). As shown in Fig. 4B, wound healing of the CNE2 cell layer was inhibited after FoxC1 knockdown by siRNA. These results demonstrated that the migratory and invasive capabilities of NPC cells were deceased following downregulation of FoxC1.
Discussion

The present study revealed that FoxC1 was overexpressed in NPC tissues as compared with that in chronically inflamed nasopharyngeal tissues. These results were consistent with those obtained from cell lines, which showed high FoxC1 expression,
while the NP69 immortalized normal nasopharyngeal epithelial cell showed low FoxC1 expression. Furthermore, high FoxC1 expression in NPC tissues was correlated with aggressive phenotypes with large tumor size, lymph node metastasis, distant metastasis and advanced clinical stage. These results implied that FoxC1 is involved in the development and progression in NPC. In addition, knockdown of FoxC1 significantly decreased the migratory, invasive and wound healing capacities of CNE2 cells in vitro. The results from clinical samples and cultured NPC cell lines supported the notion that FoxC1 contributes to aggressive phenotypes in NPC.

The EMT is a key event involved in tumor invasiveness and metastasis and is regulated by several transcription factors during tumor progression, including Twist, Snai1, Slug, Goosecoid, zinc finger E-box binding homeobox 1 and Smad-interacting protein 1 (25). FoxC1 was recently reported to be a transcriptional factor involved in the EMT (10). In the present study, high FoxC1 was correlated with upregulated mesenchymal markers (vimentin, fibronectin and N-cadherin) but not with epithelial markers (E-cadherin and β-catenin) in NPC tissues as well as in cell lines in vitro. Furthermore, the roles of epithelial and mesenchymal markers in the motility of NPC cells were verified by FoxC1 knockdown. Following downregulation of the mesenchymal markers, the migratory and invasive capacities of CNE2 cells were inhibited in vitro.

In the process of EMT, epithelial cells lose their cell-cell adhesion abilities, while cell-extracellular matrix adhesion is enhanced (8). Fibronectin is a high-molecular weight (~440 kDa) glycoprotein, which binds to extracellular matrix components and is thereby involved in cell adhesive and migratory processes (26). Fibronectin expression was reported to be increased in lung cancer, particularly in non-small cell lung carcinoma. The adhesion of lung carcinoma cells to fibronectin enhances their tumorigenicity and confers resistance to apoptosis-inducing chemotherapeutic agents (27,28). N-cadherin is a calcium-dependent cell-cell adhesion glycoprotein, which is abundant in cancer cells and facilitates transendothelial migration (29). Vimentin is responsible for maintaining cell shape, integrity of the cytoplasm and stabilization of cytoskeletal interactions (30).

The results of the present study showed that FoxC1 expression was positively associated with the expression of fibronectin, N-cadherin and vimentin, which all contributed to the migratory and invasive properties of CNE2 cells.

E-cadherin is a component of an E-cadherin/catenin adhesion complex located to adherens junctions, which are disrupted in cancer. Downregulated E-cadherin in cancer, particularly in advanced cases, leads to the disintegration of adherent junctions, followed by release of β-catenin and its translocation to the nucleus (8). However, the present study showed that in NPC, FoxC1 was not associated with E-cadherin and β-catenin expression. In hepatocellular carcinoma cells, it was previously shown that FoxC1 transactivates the expression of Snai1, a transcriptional inhibitor of E-cadherin, (10,32,33). In human breast cancer, the expression of FoxC1 is also negatively correlated with the expression of E-cadherin and β-catenin (18). The underlying mechanism of how FoxC1 regulates E-cadherin is still required to be elucidated. The results of the present

Figure 4. FoxC1 knockdown by siRNA decreases the migrative and invasive ability of CNE2 cells in vitro. (A) Giemsa staining showed that the number of migrated and invaded cells was markedly decreased following FoxC1 knockdown. (B) Wound healing assay showing that knockdown of FoxC1 by siRNA reduced the distance of migration of CNE2 cells. Values are expressed as the mean ± standard deviation. "P<0.01. Fox, forkhead box; NC, negative control; siRNA, small interfering RNA.
study implied that in NPC, FoxC1 is involved in the EMT by increasing cell-extracellular matrix adhesion rather than disrupting adherens junctions. In conclusion, the present study showed that FoxC1 was overexpressed and involved in the process of EMT through upregulating fibronectin, vimentin and N-cadherin, which contributed to cell migration and invasion in human NPC. These data suggested that FoxC1 is a potential promotor of the EMT and a prospective therapeutic target in NPC.

Acknowledgements

The present study was supported by the Natural Science Foundation of Guangxi Province (grant no. 2011jjD40031).

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, et al: Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 6: 32, 2008.
3. Zhou J, Lin YC, Kim J You L, Xu Z, He B and Jablons DM: Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck 30: 946-963, 2008.
4. Wei WI and Shams J: Nasopharyngeal carcinoma. Lancet 365: 2041-2054, 2005.
5. Wang R, Wu F, Liu H, Wei B, Feng G, Li G, Liu M, Yan H, Zhu J, Zhang Y and Hu K: Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: Long-term outcome of a multicenter prospective study. J Cancer Res Clin Oncol 139: 139-145, 2013.
6. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
7. Brabletz T: EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell 22: 699-701, 2012.
8. Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15: 178-196, 2014.
9. Cai LM, Lyu XM, Luo WR, Cui XF, Ye YF, Yuan CC, Peng QX, Wu DH, Liu TF, Wang E, et al: EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene 34: 2156-2165, 2015.
10. Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z, Zhang Y, Hu H, Fan D, Nie Y and Wu K: Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 57: 610-624, 2013.
11. Payalaksi H, Moazzenni H, Yazdani S, Rassouli P, Arefian E, Jaberi E, Arash EH, Gilani AS, Fan JB, April C, et al: FOXC1 in human trabecular meshwork cells is involved in regulatory pathway that includes miR-204, MEIS2 and ITGB1. Exp Eye Res 112: 112-123, 2013.
12. Khan AO, Aldahmesh MA, Mohamed JY and Alkuraya FS: Congenital glaucoma with acquired peripheral circumferential iris degeneration. J AAPOS 17: 105-107, 2013.
13. Ray PS, Wang J, Qu Y, Sim MS, Shamoni J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, et al: FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 70: 3870-3876, 2010.
14. Xu ZY, Ding SM, Zhou L, Xie HY, Chen KJ, Zhang W, Xing CY, Guo HJ and Zheng SS: FOXC1 contributes to microvascular invasion in primary hepatocellular carcinoma via regulating epithelial-mesenchymal transition. Int J Biol Sci 8: 1130-1141, 2012.
15. Wang L, Gu F, Liu CY, Wang RJ, Li J and Xu JY: High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 34: 853-858, 2013.
16. Nagel S, Meyer C, Kaufmann M, Drexler HG and MacLeod RA: Deregulated FOX genes in Hodgkin lymphoma. Genes Chromosomes Cancer 53: 917-933, 2014.
17. Wei LX, Zhou RS, Xu TH, Wang JG and Yuan MH: High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients. Tumour Biol 34: 941-946, 2013.
18. Blouhstein-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antonescu RC, et al: Cell type-specific and DNA methylation patterns in the human breast. Proc Natl Acad Sci USA 105: 14076-14081, 2008.
19. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, et al: Core epithelial-to-mesenchymal transition interactome gene expression signature is associated with claudin-low and metastatic breast cancer subtypes. Proc Natl Acad Sci USA 107: 15449-15454, 2010.
20. Sizemore ST and Keri RA: The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression. J Biol Chem 287: 24631-24640, 2012.
21. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, et al: Prognostic value of a microRNA signature in nasopharyngeal carcinoma: A microRNA expression analysis. Lancet Oncol 13: 633-641, 2012.
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th ed. Springer, New York, 2009.
23. Zhang XL, Huang CX, Zhang J, Inoue A, Zeng SE and Xiao SJ: CtBP1 is involved in epithelial-mesenchymal transition and is a potential therapeutic target for hepatocellular carcinoma. Oncol Rep 30:809-814, 2013.
24. Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, et al: Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 56: 95-106, 2007.
25. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
26. Pankov R and Yamada KM: Fibronectin at a glance. J Cell Sci 115: 3861-3863, 2002.
27. Williams CM, Engler AJ, Sloane RD, Galante LL and Schwarzbauer JE: Fibronectin expression modulates mammary epithelial cell proliferation during acinar differentiation. Cancer Res 65: 315-323, 2005.
28. Han S, Khuri FR and Roman J: Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66: 315-323, 2006.
29. Ramis-Conde I, Chaplain MA, Anderson AR and Draso D: Multi-scale modelling of cancer cell intravasation: The role of cadherins in metastasis. Phys Biol 6: 016008, 2009.
30. Ogrodnik M, Salmonowicz H, Brown R, Turkowski J, Sredniawa W, Pattabiraman S, Amen T, Abraham AC, Eichler N, Lyakhovetsky R and Kaganovich D: Dynamic JUNQ inclusion bodies are asymmetrically inherited in mammalian cell lines through the asymmetric partitioning of vimentin. Proc Natl Acad Sci USA 111: 8049-8054, 2014.
31. Wang W, Li X, Zhang W, Li Y, Yi M, Yang J, Zeng Z, Colvin Wanshura LE, McCarthy JB, Fan S, et al: Oxidoredox-nitro domain containing protein 1 (NOR1) expression suppresses slug/vimentin but not snail in nasopharyngeal carcinoma: Inhibition of EMT in vitro and in vivo in mice. Cancer Lett 348: 109-118, 2014.
32. Camo A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.
33. Maille E, Sancho F, Franci C, Domínguez D, Monfar M, Baulida J and García De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84-89, 2000.